Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression

Arthritis Research and Therapy

Volumn 8, Issue 6, 2006, Pages

  Ochaion, Avivit ^a,b   Bar Yehuda, Sara ^a   Cohn, Shira ^a,b   Del Valle, Luis ^c   Perez Liz, Georginia ^c   Madi, Lea ^a   Barer, Faina ^a   Farbstein, Motti ^a   Fishman Furman, Sari ^a   Reitblat, Tatiana ^d   Reitblat, Alexander ^d   Amital, Howard ^e   Levi, Yair ^e   Molad, Yair ^f   Mader, Reuven ^g   Tishler, Moshe ^h   Langevitz, Pnina ⁱ   Zabutti, Alexander ^a   Fishman, Pnina ^a  

^a Can Fite BioPharma Ltd   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BARZILAI MEDICAL CENTER   (Israel)

^e MEIR MEDICAL CENTER   (Israel)

^f Rabin and Schneider Medical Centers   (Israel)

^g HAEMEK MEDICAL CENTER   (Israel)

^h ASSAF HAROFEH MEDICAL CENTER   (Israel)

ⁱ SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE; ADENOSINE A3 RECEPTOR; ANTIINFLAMMATORY AGENT; METHOTREXATE;

ANALOGS AND DERIVATIVES; ANIMAL; ARTHRITIS; BIOSYNTHESIS; DRUG COMBINATION; DRUG EFFECTS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LEWIS RAT; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ADENOSINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS; BLOTTING, WESTERN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOCYTES, MONONUCLEAR; METHOTREXATE; MIDDLE AGED; RATS; RATS, INBRED LEW; RECEPTOR, ADENOSINE A3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 34748913494     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2078     Document Type: Article

References (29)

1. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985, 312:818-822.
2. Chan L, Cronstein BN: Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002, 4:266-273.
3. Baggott JE, Morgan SL, Sams WM, Linden J: Urinary adenosine and aminoimidazolcarboxamide excretion in methotrexatetreated patients with psoriasis. Arch Dermatol 1999, 135:813-817.
4. Laghi Pasini F, Capecchi PL, Di Perri T: Adenosine plasma levels after low-dose methotrexate administration. J Rheumatol 1997, 24:2492-2493.
5. Cronstein BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994, 76:5-13.
6. Eigler A, Greten TF, Sinha B, Haslberger C, Sullivan GW, Endres S: Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis. Scand J Immunol 1997, 45 132-139.
7. Mabley J, Soriano F, Pacher P, Hasko G, Marton A, Wallace R, Salzman A, Szabo C: The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol 2003, 466 323-329.
8. Sullivan GW: Adenosine A2A receptor agonists as anti-inflammatory agents. Curr Opin Investig Drugs 2003, 4:1313-1319.
9. Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, Cronstein BN: Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003, 48:240-247.
10. Szabo C, Scott GS, Virag L, Egnaczyk G, Salzman AL, Shanley TP, Hasko G: Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists Br J Pharmacol 1998, 125:379-387.
11. Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M, Ochaion A, Weinberger A, Fishman P: The antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol 2005, 32:469-476.
12. Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S, Baharav E: The PI3K-NF-κB signal transduction pathway is involved in mediating the anti-inflammatory effect of IBMECA in adjuvant induced arthritis. Arthritis Res Ther 2006, 8:R33.
13. Gessi S, Cattabriga E, Avitabile A, Gafa' R, Lanza G, Cavazzini L, Bianchi N, Gambari R, Feo C, Liboni A, et al.: Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res 2004, 10:5895-5901.
14. van Troostenburg AR, Clark EV, Carey WD, Warrington SJ, Kerns WD, Cohn I, Silverman MH, Bar-Yehuda S, Fong KL, Fishman P: Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther 2004, 42:534-542.
15. Nahir MA, Reitblat T, Molad Y, Rosner I, Mader R, Caspi D, Tishler M, Langevitz P, Rubinow A, Green L, et al.: Targeting the A3 adenosine receptor to combat arthritis: Early phase II study in RA patients treated with CF101. In Proceedings of the 2005 ACR/ARHP Annual Scientific Meeting; 12-17 November 2005; San Diego, CA, USA Hoboken, NJ: John Wiley & Sons; 2005:1235.
16. Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA: Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: Results from the RADIUS observational registry. Curr Med Res Opin 2006, 22:185-198.
17. Allegra CJ, Drake JC, Jolivet J, Chabner BA: Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985, 82:4881-4885.
18. Allegra CJ, Hoang K, Yeh GC, Drake JC, Baram J: Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J Biol Chem 1987, 262:13520-13526.
19. Baggott JE, Vaughn WH, Hudson BB: Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986, 236:193-200.
20. Yaar R, Cataldo LM, Tzatsos A, Francis CE, Zhao Z, Ravid K: Regulation of the A3 adenosine receptor gene in vascular smooth muscle cells: Role of a cAMP and GATA element. Mol Pharmacol 2002, 62:1167-1176.
21. Black RG Jr, Guo Y, Ge ZD, Murphree SS, Prabhu SD, Jones WK, Bolli R, Auchampach JA: Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. Circ Res 2002, 91:165-172.
22. Dougherty C, Barucha J, Schofield PR, Jacobson KA, Liang BT: Cardiac myocytes rendered ischemia resistant by expressing the human adenosine A1 or A3 receptor. FASEB J 1998, 12:1785-1792.
23. Dhalla AK, Shryock JC, Shreeniwas R, Belardinelli L: Pharmacology and Therapeutic application of A1 adenosine receptor ligands. Curr Top Med Chem 2003, 3:369-385.
24. Madi L, Bar-Yehuda S, Barer F, Ardon E, Ochaion A, Fishman P: A3 adenosine receptor activation in melanoma cells: Association between receptor fate and tumor growth inhibition. J Biol Chem 2003, 278:42121-42130.
25. Fishman P, Bar-Yehuda S, Ardon E, Rath-Wolfson L, Barrer F, Ochaion A, Madi L: Targeting the A3 adenosine receptor for cancer therapy: inhibition of Prostate carcinoma cell growth by A3AR agonist. Anticancer Res 2003, 23:2077-2083.
26. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J: International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001, 53:527-552.
27. Schlotzer-Schrehardt U, Zenkel M, Decking U, Haubs D, Kruse FE, Junemann A, Coca-Prados M, Naumann GO: Selective upregulation of the A3 adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma Invest Ophthalmol Vis Sci 2005, 46:2023-2034.
28. Walker BA, Jacobson MA, Knight DA, Salvatore CA, Weir T, Zhou D, Bai TR: Adenosine A3 receptor expression and function in eosinophils. Am J Respir Cell Mol Biol 1997, 16:531-537.
29. Gessi S, Varani K, Merighi S, Cattabriga E, Avitabile A, Gavioli R, Fortini C, Leung E, Mac Lennan S, Borea PA: Expression of A3 adenosine receptors in human lymphocytes: Up-regulation in T cell activation. Mol Pharmacol 2004, 65:711-719.